U.S. FDA approves AbbVie hepatitis C drug, costs $83,319 for 12 weeks

December 20, 2014 1:02 AM

5 0

(Reuters) - U.S. health regulators on Friday approved AbbVie's all-oral treatment for hepatitis C, and the company said the drug would cost $83,319 for a typical 12-week plan, a bit below its huge selling competitor Solvadi from Gilead Sciences.

Gilead's Sovaldi treatment stole headlines last year with its $84,000 price tag and set off a national debate about whether drug prices have climbed too high.

Read more

To category page

Loading...